Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of tenofovir disoproxil and telbivudine on the growth and development of infants by blocking mother-to-child transmission of hepatitis B virus

Chengjing Tao¹, Jiannv Hu¹, Suying Zhang¹, Xiuli Bai¹, Chun Zhao², Zhongbao Zuo³, Shourong Liu²

¹Department of Obstetrics and Gynecology, Hangzhou Xixi Hospital, Hangzhou, China; ²Department of Hepatology, Hangzhou Xixi Hospital, Hangzhou, China; ³Department of Clinical Laboratory, Hangzhou Xixi Hospital, Hangzhou, China.

For correspondence:- Shourong Liu Email: Tcj309013910@126.com Tel:+8618072980585

Accepted: 30 August 2022 Published: 30 September 2022

Citation: Tao C, Hu J, Zhang S, Bai X, Zhao C, Zuo Z, et al. Effect of tenofovir disoproxil and telbivudine on the growth and development of infants by blocking mother-to-child transmission of hepatitis B virus. Trop J Pharm Res 2022; 21(9):1985-1991 doi: 10.4314/tjpr.v21i9.24

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of tenofovir disoproxil and telbivudine on the growth and development of infants after blocking mother-to-child transmission (MTCT) of hepatitis B virus (HBV).

Methods: Seventy pregnant women with chronic hepatitis B (CHB) were recruited and allocated to tenofovir disoproxil group (n = 35) and telbivudine group (n = 35) using random number table method. Tenofovir disoproxil group was given 300 mg tenofovir disoproxil orally four times daily, while telbivudine group was given telbivudine 600 mg orally four times daily.

Results: After treatment, both groups showed no significant differences in serum HBV-DNA and ALT levels before delivery and 3 months after delivery (p > 0.05). Both groups showed no remarkable differences in the incidence of hypohydramnios, cholestasis, hypothyroidism, anemia, prolonged labor, fetal distress, and placental adhesions (p > 0.05). Both groups showed no significant differences in the rates of premature rupture of membranes, preterm birth, vaginal delivery, and cesarean section (p > 0.05). Both groups showed no significant differences in neonatal sex, gestational age at birth, weight, length, and Apgar scores (p > 0.05). The differences in the positive rates of HBVsAg, HBsAb, and HBeAg at birth and at 12 months were not statistically noticeable (p > 0.05).

Conclusion: Tenofovir disoproxil and telbivudine reduce HBV-DNA levels, effectively blocks MTCT, and have a similar safety profile for infants. Further investigations to confirm their safety as drugs for antiviral therapy in CHB pregnant women at 24 weeks of gestation is required.

Keywords: Tenofovir disoproxil, Telbivudine, Blocking hepatitis B virus, Mother-to-child transmission, Infants, Growth and development